07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

IS Pharma, Sinclair deal

The boards of both companies agreed to merge and form Sinclair IS Pharma plc . The newco, which will be headquartered in the U.K., will focus on developing therapies for dermatology, cancer, critical care and...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Company News

IS Pharma, Sinclair deal

IS Pharma and Sinclair said they are in advanced discussions for a potential merger of the biotechs. Under the potential deal terms, IS Pharma shareholders will receive 2.7 Sinclair shares per IS Pharma share. After...
00:54 , Aug 27, 2010 |  BC Extra  |  Financial News

Sinclair planning offering

Sinclair Pharma plc (LSE:SPH) plans to raise L19 million ($29.6 million) through the sale of 67.9 million shares at 28p in a placing and open offer underwritten by Singer Capital Markets. The price is an...
02:02 , Dec 11, 2009 |  BC Extra  |  Financial News

Sinclair raises L18.2 million

Sinclair Pharma plc (LSE:SPH) raised L18.2 million ($29.7 million) through the sale of 56.7 million shares at 32p in a placing and open offer. The price is a 29% discount to Sinclair's close of 45p...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Financial News

Sinclair amends placing and open offer

Sinclair Pharma plc (LSE:SPH), Godalming, U.K.   Business: Dermatology, Dental   Date announced: 10/29/09   Type: Placing and open offer   To be raised: Up to £18 million ($29.3 million)   Price: 32p   Investor:...
07:00 , Oct 19, 2009 |  BC Week In Review  |  Financial News

Sinclair proposes placing and open offer

Sinclair Pharma plc (LSE:SPH), Godalming, U.K.   Business: Dermatology, Dental   Date announced: 10/12/09   Type: Placing and open offer   To be raised: Up to £25 million ($39.4 million)   Shares: TBD   Price:...
07:00 , Oct 19, 2009 |  BC Week In Review  |  Company News

Sinclair, Solvay sales and marketing update

Sinclair will acquire worldwide rights, excluding the U.K. and Italy, to Flammazine and Flammacerium from Solvay for €17.5 million ($25.7 million). The silver sulfadiazine topical creams are marketed to treat and prevent infections in burn...
07:00 , Oct 19, 2009 |  BioCentury  |  Finance

Ebb & Flow

Armed with two Special Protocol Agreements from FDA, Amarin Corp. (NASDAQ:AMRN) has been able to resurrect its fortunes by convincing investors that a compound that disappointed in its original indication of Huntington's disease deserves a...
00:36 , Oct 13, 2009 |  BC Extra  |  Company News

Sinclair acquiring Solvay drugs, names new CEO

Sinclair Pharma plc (LSE:SPH) will acquire worldwide rights, excluding the U.K. and Italy, to Flammazine and Flammacerium from Solvay S.A. (Euronext:SOLB) for EUR 17.5 million ($25.7 million). The silver sulfadiazine topical creams are marketed to...
08:00 , Jan 26, 2009 |  BC Week In Review  |  Company News

York Pharma, Solvay deal

Dermatology company York returned worldwide marketing rights to Solvay's Flammazine silver sulfadiazine and Flammacerium silver sulfadiazine/cerium nitrate after York lost its loan facility. York's lender Fortress Credit Corp. called for repayment of the facility after...